This company has been marked as potentially delisted and may not be actively trading. Cleveland BioLabs (CBLI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CBLI vs. SCPS, EVLO, CMRA, ARDS, STAB, AMPE, EFTR, CLVR, HSTO, and ONCSQShould you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), Clever Leaves (CLVR), Histogen (HSTO), and OncoSec Medical (ONCSQ). These companies are all part of the "medical" sector. Cleveland BioLabs vs. Its Competitors Scopus BioPharma Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Clever Leaves Histogen OncoSec Medical Cleveland BioLabs (NASDAQ:CBLI) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do insiders and institutionals hold more shares of CBLI or SCPS? 5.1% of Cleveland BioLabs shares are held by institutional investors. 1.0% of Cleveland BioLabs shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CBLI or SCPS more profitable? Scopus BioPharma's return on equity of 0.00% beat Cleveland BioLabs' return on equity.Company Net Margins Return on Equity Return on Assets Cleveland BioLabsN/A -32.84% -31.29% Scopus BioPharma N/A N/A N/A Which has more volatility & risk, CBLI or SCPS? Cleveland BioLabs has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Which has better valuation & earnings, CBLI or SCPS? Cleveland BioLabs has higher revenue and earnings than Scopus BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCleveland BioLabs$260K0.00-$2.40MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Does the media prefer CBLI or SCPS? In the previous week, Cleveland BioLabs' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Cleveland BioLabs Neutral Scopus BioPharma Neutral SummaryCleveland BioLabs beats Scopus BioPharma on 4 of the 7 factors compared between the two stocks. Get Cleveland BioLabs News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLI vs. The Competition Export to ExcelMetricCleveland BioLabsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$782.30M$5.56B$9.47BDividend YieldN/A4.84%4.31%4.17%P/E RatioN/A1.3029.3723.99Price / SalesN/A25.47444.7496.71Price / CashN/A19.5635.8458.51Price / BookN/A6.598.085.58Net Income-$2.40M-$4.20M$3.26B$265.35M Cleveland BioLabs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLICleveland BioLabsN/AN/AN/AN/A$5K$260K0.004SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+1,350.0%$3KN/A0.0020EFTReFFECTOR Therapeutics0.0768 of 5 stars$0.00+200.0%N/A-99.5%$3KN/A0.0010CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560HSTOHistogenN/A$0.00flatN/AN/A$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies Scopus BioPharma Alternatives Evelo Biosciences Alternatives Comera Life Sciences Alternatives Aridis Pharmaceuticals Alternatives Statera Biopharma Alternatives Ampio Pharmaceuticals Alternatives eFFECTOR Therapeutics Alternatives Clever Leaves Alternatives Histogen Alternatives OncoSec Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBLI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
